Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2091730 | 0.87 | TDP1 (0.61) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL2091999 | 0.85 | HRH1 (0.62) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL4812510 | 0.81 | CHRNA7 (0.53) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL29485692 | 0.80 | CHRNA7 (0.74) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL724866 | 0.80 | CHRNA7 (0.74) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL8193864 | 0.80 | CHRNA7 (0.57) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL8193865 | 0.80 | CHRNA7 (0.62) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL273379 | 0.80 | CHRNA7 (0.57) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL26860610 | 0.80 | CHRNA7 (0.57) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 | |
| SCHEMBL9755554 | 0.79 | CHRNA7 (0.52) | CHRNA7CYP2A6L3MBTL1TDP1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | claimed |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741938-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | ABBVIE INC (US) | 2013-11-28 | — | — | US | disclosed |
| US-8524753-B2 | Compounds that are useful for improving pharmacokinetics | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2012-12-06 | — | — | US | disclosed |
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | ABBOTT LABORATORIES | 2002-10-10 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002062761-A1 | AMINAL DIONES AS POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CHRNA7 190/4885CYP2A6 1746/4885L3MBTL1 869/4885 |
| US-20130317071-A1 | NOVEL COMPOUNDS THAT ARE USEFUL FOR IMPROVING PHARMACOKINETICS | CYP11B1, CYP11B2, CYP7A1 | CHRNA7 4470/4885CYP2A6 39/4885L3MBTL1 4712/4885 |
| US-20120309762-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CHRNA7 2950/4885CYP2A6 23/4885L3MBTL1 4679/4885 |
| US-20020147230-A1 | Aminal Diones as potassium channel openers | KCNJ2, KCNJ11, KCNH1 | CHRNA7 247/4885CYP2A6 505/4885L3MBTL1 1654/4885 |
| US-20130131085-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CHRNA7 2950/4885CYP2A6 23/4885L3MBTL1 4679/4885 |
| US-20140243340-A1 | CYTOCHROME P450 OXIDASE INHIBITORS AND USES THEREOF | CYP3A43, CYP3A5, POR | CHRNA7 2950/4885CYP2A6 23/4885L3MBTL1 4679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.